Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Q -- Prospective Evaluation of Immunologic and IMMunogenetic susceptibility to Mycobacterium tuberculosis infection and progression to disease

Active
2007-Q-09468Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract involves a sole source award to Laboratories at Bonfils, Inc. for performing specialized HLA Class II typing assays as part of a study on immunologic and immunogenetic susceptibility to Mycobacterium tuberculosis infection and disease progression. The CDC previously funded this laboratory in 2002, recognizing its unique capability and access to existing data crucial for maintaining consistency and scientific validity across all samples tested. The contract requires HLA Class II typing for DRB1 and DQB1 alleles in 486 DNA samples drawn from whole blood, using Luminex DNA micro-particle bead technology, with results decoded and submitted back to CDC. This work supports the development and testing of new tuberculosis vaccines and must be completed within a four-month period from award. This contract is awarded under Simplified Acquisition procedures with no competitive solicitation, reflecting CDC’s discretion to award based on prior relationship and specialized capabilities. Contractors must be registered in the Central Contractor Registration system to be eligible. Communication and notifications related to the contract are handled through official government channels, with submissions and inquiries directed to the designated contract specialist. The purpose of this contract is to ensure continuity and comparability in HLA assay results critical to advancing tuberculosis vaccine research.

General Info

Sole source contract to Bonfils for HLA typing in 486 samples using Luminex technology within four months.

Agency

N/A

NAICS

541380 - Testing Laboratories and Services

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Catherine E JohnsonContract Specialist

Full Description

Show more
Title: Prospective Evaluation of Immunologic and Immunogenetic Susceptibility to Mycobacterium Tuberculosis infection and progression to disease The Centers for Disease Control and Prevention, National Center for HIV, Hepatitis, STD, and Tuberculosis Prevention intends to award a sole source contract under Simplified Acquisition procedures to Laboratories at Bonfils, Inc., 717 Yosemite Street, Denver, Colorado 80230-6918, the only source that has access to prior data required to perform this contract. In 2002, CDC funded Laboratories At Bonfils to perform the HLA testing required for this project. Developing HLA typing assays and performing HLA testing is a specialized skill. The sensitivity and specificity of HLA assays for the same parameter vary from laboratory to laboratory. To maintain comparability of results, it is important that all samples be tested in a single laboratory. It is essential to the scientific quality of the results that the remainder of the HLA assays for the study also be performed in the same laboratory. Fifteen thousand of the 1,986 samples have been tested and collected for this project. CDC is now preparing the final 486 samples for HLA typing. The vendor will perform HLA Class II typing for DRB1 and DQB1 for 486 DNA samples through specimen number 1986. DNA will be extracted from whole blood samples. DNA samples will be shipped to the vendor for HLA testing. HLA Class II typing for DRB and DRQ alleles will be performed using Luminex DNA micro-particle bead technology. Results will be decoded by the vendor before submission to CDC. Results of this work serve as a critical step in the process of developing and testing new candidate vaccines for tuberculosis. The period of performance is 4 months from date of award. This is not a request for competitive proposals and no solicitation is available. A determination by the Government not to compete this proposed action based on response to this notice is solely with the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Contractors must be registered in the Central Contractor Registration (CCR). Contractors may register by calling +1 (555) 000-0000 or register via the Internet at www.ccr.gov. Registration Notification of any changes shall be made only through FedBizOpps, http://ww.fedbizopps.gov. Capability statements may be faxed to +1 (555) 000-0000, ATTN: Ms. Johnson or emailed to contact@example.gov. The date specified for receipt is April 11, 2007, 9:00 a.m. EST.

Similar Contracts

Same NAICS industry code

Earlier notices in this NAICS code

Posted before this notice, open and closed

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS